Glibenclamide (Glyburide), K+ channel blocker

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome P450 3A4 (CYP3A4) is part of the cytochrome P450 superfamily and plays an important role in drug metabolism. It has a mass of around 57 kDa and is widely expressed in liver and intestinal tissues. Known also as CYP3A4 it is responsible for oxidizing small foreign organic molecules like toxins or drugs so the body can eliminate them. Other proteins like CYP2C9 CYP2C8 and CYP2C19 are related due to shared enzymatic functions. Additionally Maxi potassium channels including SLO KCNMB1 and KCNMB4 facilitate potassium ion flow across cell membranes influencing cell excitability and signaling. SUR1 Kir6.2 and related ABC transporters like ABCB11 (also named BSEP) are involved in ion channel regulation and bile acid transport respectively.

Biological function summary

CYP3A4 detoxifies harmful compounds and metabolizes pharmaceuticals which is essential for the liver's chemical processing. It works in conjunction with other cytochrome P450 enzymes such as CYP2C9 and CYP2C8 and participates in a PXR-modulated gene expression complex that enhances drug clearance. Potassium channels such as SLO coordinate with regulatory subunits like KCNMB1 to modulate neuronal activity and muscle tone. These channels integrate with Kir6.2/BIR to form structures that control cellular response to metabolic change while bile transporters like ABCB11/BSEP regulate bile salt export critical for hepatic function.

Pathways

CYP3A4 is central to the drug metabolism pathway significantly impacting the pharmacokinetic properties of many medications. It interacts with PXR which senses the presence of foreign substances to upregulate detoxifying enzymes. The Renin-Angiotensin-Aldosterone System (RAAS) and the potassium ion channels are related through the regulation of vascular tone and blood pressure by KCNMB1 and SUR1. These complexes interconnect to mediate hormonal balancing and renal filtration with ties to ABC transporters managing hepatic excretion of metabolic byproducts.

CYP3A4's involvement in drug metabolism has direct implications for drug-drug interactions and adverse drug reactions particularly affecting medications like glyburide and glibenclamide widely used antidiabetics. Alterations in CYP3A4 can lead to improper drug breakdown causing over-medication or incomplete therapeutic relief impacting conditions like hypertension when linked to potassium channel mutations. Relatedly KCNMB1 and SUR1 are associated with cardiovascular disorders due to their roles in blood pressure regulation and cardiac excitability. Mutations or dysregulation in these proteins and pathways can contribute to conditions such as hypertension and heart failure.